1. Home
  2. VZLA vs MESO Comparison

VZLA vs MESO Comparison

Compare VZLA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VZLA

Vizsla Silver Corp.

HOLD

Current Price

$3.56

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.48

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VZLA
MESO
Founded
2017
2004
Country
Canada
Australia
Employees
N/A
81
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.2B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
VZLA
MESO
Price
$3.56
$14.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$7.00
N/A
AVG Volume (30 Days)
9.0M
242.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$644.56
Revenue Next Year
N/A
$38.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.69
$9.61
52 Week High
$7.19
$21.50

Technical Indicators

Market Signals
Indicator
VZLA
MESO
Relative Strength Index (RSI) 35.75 36.13
Support Level $3.35 $14.35
Resistance Level $4.33 $16.33
Average True Range (ATR) 0.22 0.56
MACD -0.00 -0.06
Stochastic Oscillator 1.10 27.35

Price Performance

Historical Comparison
VZLA
MESO

About VZLA Vizsla Silver Corp.

Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: